DLAT ELISA kit
- Known as:
- DLAT Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-DLAT-Mu
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- DLAT ELISA kit
Related genes to: DLAT ELISA kit
- Gene:
- DLAT NIH gene
- Name:
- dihydrolipoamide S-acetyltransferase
- Previous symbol:
- DLTA
- Synonyms:
- PDC-E2, E2
- Chromosome:
- 11q23.1
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2018-12-14
Related products to: DLAT ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: DLAT ELISA kit
- Recent pharmacological breakthroughs have identified cuproptosis as a distinct, regulated cell death (RCD) pathway driven by mitochondrial copper overload. Unlike traditional RCDs such as apoptosis or ferroptosis, cuproptosis is characterized by the direct binding of excess copper to lipoylated enzymes of the tricarboxylic acid (TCA) cycle, notably the E2 subunit of pyruvate dehydrogenase (DLAT). This interaction triggers toxic protein aggregation and the destabilization of iron-sulfur (Fe-S) cluster proteins, culminating in metabolic collapse. This review provides an updated and integrative overview of the molecular machinery governing copper homeostasis, highlighting ferredoxin 1 (FDX1) and lipoyl synthase (LIAS) as pivotal metabolic gatekeepers. We summarize opportunities and unresolved challenges in leveraging copper ionophores (e.g., elesclomol and disulfiram) and high-affinity chelators (e.g., tetrathiomolybdate) across malignant and non-neoplastic diseases. Furthermore, we address the translational challenges of precision delivery, including the use of nanoparticle-based systems to enhance therapeutic indices and the identification of biomarkers for patient stratification. By integrating recent pre-clinical and early clinical data (2023-2025), we suggest that targeting the mitochondrial-copper axis represents a promising, yet still experimentally grounded, avenue in precision medicine, while emphasizing current limitations in biomarker validation, delivery selectivity, and safety profiling. - Source: PubMed
Publication date: 2026/04/18
El-Nablaway MohammadAttia Mohamed IbrahimYousef Tarek AKoushaji GhaithTarik WedadGilkaramenthi RafiullaElazab Khalid M - The prognostic values of cuproptosis-related genes (CRGs) in gastric cancer with lymph node metastasis (GCLM), especially in the tumor immune microenvironment (TIME), remain unclear. We analyzed the expression, mutation, immunity, drug sensitivity, and prognostic value of CRGs in GCLM using TCGA and GEO cohorts. Consensus clustering was performed to identify CRG subtypes, with differences characterized by multi-omics analysis. A CRG-based prognostic risk score and immune score were constructed for individualized assessment, and the role of CRGs was validated through in vitro and in vivo experiments. Consensus clustering revealed that CRGs were significantly enriched in biological processes related to mitosis and energy metabolism, as well as in immune-related and cancer-associated pathways. Four distinct CRG subtypes were identified, showing marked differences in expression profiles, prognosis, genetic alterations, TIME, and chemotherapeutic drug sensitivity. We developed an exploratory CRG-based prognostic risk score for preliminary individualized assessment, and the functional relevance of CRGs in GCLM was further validated through in vitro experiments. Among these, FDX1, LIAS, DLAT, MTF1, and GLS were identified as key determinants of overall survival in patients with GCLM, with FDX1 emerging as a potential independent prognostic factor. Notably, upregulation of FDX1 significantly suppressed lymph node metastasis of gastric cancer cells in a mouse popliteal lymph node metastasis model. Our data uncovers FDX1 might be a potential favorable prognostic factors in GCLM patients. These findings may improve our understanding of CRGs in GCLM and provide new in-sights for assessing prognosis and developing more effective treatment strategies. - Source: PubMed
Publication date: 2026/05/10
Zhang TianhaoLiu JianqiuDuan PengLi ZikangHuang ZhixinZhao ZeyuCheng YangLiang ZhiChen JianhuiCai MeilanMa Jinping - Cuproptosis, an emerging form of programmed cell death, is capable of inducing mitochondrial dysfunction. Moreover, the PI3K-AKT-mTOR signaling pathway contributes to tumor cell progression by reprogramming mitochondrial morphology and function. In this study, we have designed copper complex nanoparticles (NP) and PI3K-AKT-mTOR inhibitor Alpelisib nanoparticles (NP) that enhance the efficacy of cuproptosis-based therapies. NP triggers mitochondrial dysfunction and promotes the aggregation of lipoylated dihydrolipoamide S-acetyltransferase (DLAT), while NP inhibits the PI3K-AKT-mTOR signaling pathway to induce apoptosis. The combination of these two nanoparticles (NP+NP) effectively activates the antitumor responses in the tumor microenvironment (TME). When combined with an anti-programmed cell death protein 1 antibody (α-PD-1), NP+NP significantly inhibits tumor progression and activates antitumor immunity, offering a promising strategy for liver cancer treatment. - Source: PubMed
Publication date: 2026/05/05
Wu LeiNa JintongLiu XiyuTang DongshengYang ZhungangCao ZhengHe XinyueXiao HaihuaZhong LipingLiao YuanZhao Yongxiang - Cuproptosis represents a promising therapeutic strategy for cancer; however, its clinical application remains limited. We observed elevated copper levels and increased expression of DLAT, a key procuproptosis gene, in colorectal cancer (CRC) tissues, suggesting inherent susceptibility to cuproptosis. Furthermore, NAT10 enhances DLAT mRNA stability by mediating its N-acetylcytidine (ac4C) modification, thereby promoting cuproptosis. We also discovered that lactylation of NAT10 at lysine 426 (K426) enhances NAT10 catalytic activity. Conversely, SIRT1 mediates the delactylation of NAT10-K426, leading to the inhibition of cuproptosis. The combination of elesclomol (a cuproptosis inducer) and selisistat (a SIRT1 inhibitor) effectively induced cuproptosis in CRC. Notably, the reduction of soluble DLAT induced by elesclomol treatment was found to enhance NAT10-K426 lactylation. Moreover, DLAT supplementation establishes a positive feedback loop that amplifies cuproptosis. These results underscore the critical role of nonhistone NAT10 lactylation in tumor cuproptosis and highlight the therapeutic potential of targeting this pathway for CRC treatment. - Source: PubMed
Publication date: 2026/05/05
Yang Wen-DongLu Meng-RuShen QiZhou Pei-HengDiao YangXia ShanLu Ya-ChunCui Yong-QiangLi Bing-QiangXu Wen-XiaChen LinZhang ChaoMa NingGuo YaoShao Zhi-YingGe Wen-JieBai Jin - Cuproptosis, a recently identified form of programmed cell death, has an unclear role in the context of metabolic dysfunction-associated steatohepatitis (MASH). This study aims to elucidate the role of cuproptosis in the early stages of MASH progression, identify its primary regulatory factors, and delineate the associated molecular mechanisms. - Source: PubMed
Publication date: 2026/05/02
Fu XuanLi YunmengChen JingYin BaolongNasrin MahbubaHuo RuiTian Shuxin